SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase (COIN) is trending due to polarized community reactions to its recent Super Bowl commercial, with sentiment sharply divided on its effectiveness amid broader discussions of significant crypto market volatility. The debate continues on whether the stock has found a bottom or is poised for further declines, alongside anticipation for upcoming earnings.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is drawing significant attention following news of its extended $250 million capital runway through 2028, which many believe secures its operations and removes dilution concerns. The community is sharply divided, with bulls anticipating a short squeeze and another historic surge in the blockchain and molecular-marker technology stock, while skeptics argue it remains a "dilution machine" without sustained product revenue.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as the Super Bowl drives massive betting volume and user engagement, with the community actively debating the company's expanding prediction market offerings and the broader sector's evolving regulatory landscape, all ahead of its anticipated earnings report.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending after abruptly ceasing its compounded GLP-1 weight-loss pill offering amid intensified FDA scrutiny and legal threats, sparking widespread debate about the company's regulatory risks and strategic direction. The community is sharply divided, with bears pointing to management's judgment and potential lawsuits, while bulls emphasize the removal of legal overhang and the broader telehealth platform's potential for recovery and growth, especially with the upcoming Super Bowl ad.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Community excitement for TG Therapeutics is surging following Christina Applegate's Super Bowl commercial for Briumvi, which is expected to drive substantial patient awareness and market adoption. The authentic endorsement is viewed as a significant catalyst, further differentiating Briumvi amidst competitor safety concerns.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate Inc. is garnering significant attention following FDA acceptance of its NDA for CTx-1301, a potentially game-changing ADHD treatment, as the community eagerly awaits impending US patent news, fueling speculation of substantial market revaluation due to its low float.

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

PZZA is trending due to persistent buyout speculation, with community sentiment driven by reports of private equity offers at a premium to its perceived undervalued share price, alongside discussions of activist investor interest and its attractive dividend yield.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending as futures indicate strong bullish momentum leading into the week, while the community is widely discussing the Super Bowl halftime show's perceived, albeit speculative, impact on market sentiment alongside anticipation for upcoming jobs and inflation reports.

JERRY (JYAI) is a Matt Furie's artistic style; it features an AI-powered content creation hub that produces community-driven video series and art.  Jerry the Turtle, created by Matt Furie, is a character inspired by Furie’s artistic style. JERRY is also an AI-driven meme coin with an ambitious vision. The goal is to establish an AI-powered production house dedicated to creating a video series or episodes featuring characters from Matt Furie’s universe alongside those from Jerry’s world.  This unique blend of characters aims to produce the ultimate crypto-based series. Additionally, we are developing an app that will offer an exclusive, ad-free video series featuring characters from both Matt Furie’s creations and the Jerry Universe. Users will be able to download and share videos directly through the platform.  But that’s not all! A special Jerry Art Panel will showcase original Jerry characters, artwork, and fan creations—free to explore, download, and share with the community.

Jerry The Turtle By Matt Furie

Jerry The Turtle ($JYAI), an AI memecoin backed by Matt Furie, is trending with strong community enthusiasm following new exchange listings on platforms like Bitget and KuCoin Alpha, a recent developer update to counter selling pressure, and an ongoing 12-week marketing campaign including a new podcast and a Crypto Banter partnership, with many anticipating it to be the "next PEPE" and aspiring for Tier 1 exchange listings.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - VR PRF PERPETUAL USD 100 - Ser A

Strategy Inc Variable Rate Series A Perpetual Stretch Preferred

STRC is trending as it maintains its position around $100 par value, buoyed by its attractive variable dividend rate of 11.25%, with the community actively debating its role in funding MSTR's Bitcoin strategy and its viability as a high-yield income instrument.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Savant Capital LLC Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Savant Capital LLC lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 346.6% in the 3rd quarter, according to its most recent Form 13F filing with the...

Thrivent Financial for Lutherans Sells 1,978 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Thrivent Financial for Lutherans reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 20.8% in the 3rd quarter, according to its most recent filing with the SEC. The...

Wall Street Zen Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Buy

Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Sunday...

Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Murphy Pohlad Asset Management LLC

Murphy Pohlad Asset Management LLC raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 117.3% during the third quarter, according to the company in its most recent...

Prime Capital Investment Advisors LLC Buys 11,835 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Prime Capital Investment Advisors LLC boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1,852.1% during the 3rd quarter, according to its most recent 13F filing with...

Bronte Capital Management Pty Ltd. Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Bronte Capital Management Pty Ltd. lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.0% in the third quarter, according to the company in its most recent 13F...

NVO's CagriSema Outshines Semaglutide in Phase III Diabetes Study

Novo Nordisk reports that CagriSema beats semaglutide at HbA1c reduction and weight loss in a 68-week phase III diabetes study, with no weight-loss plateau.

Here's Why Gilead Sciences Stock Surged 21% in a Month 

GILD shares gain traction post Jan. 20 after NEJM data show Trodelvy plus Keytruda cut progression risk 35% in first-line PD-L1+ metastatic TNBC, signaling a new care standard.

<ul class="summary-bullets"><li>Several Wall Street firms raised price targets on Regeneron after its Q4 results.</li><li>Q4 revenue and non-GAAP earnings both exceeded Wall Street estimates.</li><li>Eylea HD sales rose sharply, while sales of the original Eylea fell.</li></ul>Regeneron Pharmaceuticals shares fell 0.4% in premarket trading on Monday as investors focused on weakness in the core Eylea business, even after multiple Wall Street firms raised their price targets following the company’s fourth-quarter (Q4) earnings report.<h2 class="st-heading-2">Analyst Calls Lift Premarket Tone</h2>Wells Fargo raised its price target on Regeneron to $800 from $745, implying about 8% upside from Friday’s close of $741.45, and maintained an ‘Equal Weight’ rating. The firm said management’s commentary on a potential extension of Dupixent’s intellectual property was encouraging. Dupixent is the company’s eczema and asthma treatment. Wells Fargo also noted upside to 2026 estimates, while adding that the stock still lacks near-term catalysts.Morgan Stanley issued a slight raise, increasing its price target to $769 from $768, pointing to a roughly 4% upside, and maintained an ‘Equal Weight’ rating. The brokerage called Q4 “uneventful” and expects Phase 3 melanoma data to be the next catalyst.Raymond James was more bullish, lifting its price target to $870 from $820, marking a 17% upside, while maintaining an 'Outperform' rating. The analyst firm said investors should focus on what they see beyond the near-term noise, reasoning that Eylea HD label enhancements should position the franchise to gain market share, and 2026 could be a key pipeline year with multiple late-stage readouts.<h2 class="st-heading-2">Eylea HD Growth Lifts Q4 Print</h2>The analyst revisions followed Regeneron’s&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/regn-stock-slips-regeneron-earnings-q4-eylea-hd-revenue/cmySjWfR4S5">Q4 earnings</a> report on Friday, which exceeded expectations despite mixed trends across its product portfolio.Revenue rose 3% year over year to $3.88 billion, topping Wall Street forecasts of $3.78 billion, according to Fiscal.ai. Non-GAAP earnings slipped 5% to $11.44 per share, but still beat analyst estimates of $10.74.Sales of Eylea HD, the company’s eye injection for retinal diseases, climbed 66% in the quarter as demand increased, though gains were partly offset by lower pricing. At the same time, sales of the original Eylea formulation fell 52%, reflecting competitive pressure, patient shifts to the high-dose version, and increased use of lower-cost alternatives. Collaboration revenue with Sanofi jumped 35%, driven primarily by stronger sales of Dupixent.Looking ahead, Regeneron forecasts non-GAAP R&amp;D spending of $5.90 billion to $6.10 billion for full-year 2026, up from $5.15 billion in fiscal 2025. The company said it now has around 45 product candidates in clinical development.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Regeneron was ‘bearish’ amid ‘high’ message volume.<a href="https://stocktwits.com/symbol/REGN">Regeneron’s stock</a> has risen 9% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regeneron Pharmaceuticals company logo is displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Regeneron Stock Slips Premarket Even After Wall Street Lifts Targets On Strong Q4 — What’s Weighing On The Stock?

Regeneron Stock - Analysts said near-term catalysts remain limited, with Phase 3 melanoma data as the next key event to watch.

Equity

Analysts said near-term catalysts remain limited, with Phase 3 melanoma data as the next key event to watch.

Best Pharmaceutical Stocks To Watch Today - February 1st

Eli Lilly and Company, Abbott Laboratories, AbbVie, Pfizer, Gilead Sciences, Regeneron Pharmaceuticals, and Bristol Myers Squibb are the seven Pharmaceutical stocks to watch today, according to...

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

REGN
Regeneron Pharmaceuticals, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest REGN News

REGNRegeneron Pharmaceuticals, Inc.